Cirio legal advisor to NeuroVive Pharmaceutical in connection with its rights issue

Cirio acts as legal advisor to NeuroVive Pharmaceutical AB (publ), listed on Nasdaq Stockholm, Small Cap, in connection with its rights issue directed to existing shareholders.

On 19 February 2020, the Board of Directors of NeuroVive resolved, subject to approval by the general meeting, to increase the company’s share capital by an issue of shares with preferential rights for existing shareholders. The Board of Directors’ resolution was approved by the extraordinary general meeting on 17 March 2020. Upon full subscription of the rights issue, the company will raise approximately MSEK 74 before issue costs. The rights issue is guaranteed to 90 percent of the rights issue, through subscription commitments from existing shareholders and guarantee commitments from investors. A prospectus will be prepared in connection with the rights issue and is expected to be published on or around 3 April 2020.

NeuroVive is a leader in mitochondrial medicine with several project in clinical trials. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH.

Cirio advises NeuroVive with a team headed by Annika Andersson (responsible partner) together with Tim Johansson, Oscar Lunde and Jesper M Johansson (Capital Markets and public M&A), Odd Swarting (Life science) and David Leffler (Intellectual Property).

For more information, please contact: